A neural network-based biomarker association information extraction approach for cancer classification  by Wang, Hong-Qiang et al.
Journal of Biomedical Informatics 42 (2009) 654–666Contents lists available at ScienceDirect
Journal of Biomedical Informatics
journal homepage: www.elsevier .com/locate /y jb inA neural network-based biomarker association information extraction approach
for cancer classiﬁcation
Hong-Qiang Wang a,*, Hau-San Wong a, Hailong Zhu b, Timothy T.C. Yip c
aDepartment of Computer Science, City University of Hong Kong, Hong Kong, China
bDepartment of RIPT, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, China
cDepartment of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China
a r t i c l e i n f o a b s t r a c tArticle history:
Received 18 August 2008
Available online 6 January 2009
Keywords:
Cancer classiﬁcation
High-throughput technology
Neural network
Biomarker Association Network1532-0464/$ - see front matter  2009 Elsevier Inc. A
doi:10.1016/j.jbi.2008.12.010
* Corresponding author.
E-mail address: hqwang@ustc.edu (H.-Q. Wang).A number of different approaches based on high-throughput data have been developed for cancer clas-
siﬁcation. However, these methods often ignore the underlying correlation between the expression levels
of different biomarkers which are related to cancer. From a biological viewpoint, the modeling of these
abnormal associations between biomarkers will play an important role in cancer classiﬁcation. In this
paper, we propose an approach based on the concept of Biomarker Association Networks (BAN) for cancer
classiﬁcation. The BAN is modeled as a neural network, which can capture the associations between the
biomarkers by minimizing an energy function. Based on the BAN, a new cancer classiﬁcation approach is
developed. We validate the proposed approach on four publicly available biomarker expression datasets.
The derived Biomarker Association Networks are observed to be signiﬁcantly different for different can-
cer classes, which help reveal the underlying deviant biomarker association patterns responsible for dif-
ferent cancer types. Extensive comparisons show the superior performance of the BAN-based
classiﬁcation approach over several conventional classiﬁcation methods.
 2009 Elsevier Inc. All rights reserved.1. Introduction
High-throughput biological technology can simultaneously
assess the levels of expression of tens of thousands of biomarkers
in tumors, and it was demonstrated that it is capable of providing
more reliable cancer classiﬁcation owing to the resultingmore com-
plete molecular understanding of tumors [1–5]. Currently, develop-
ing efﬁcient computational methods based on high-throughput
technology for cancer classiﬁcation is an important and challenging
task in pattern recognition and bioinformatics [6–8].
There have been various methods developed to address this
issue [9–11]. These methods are in general data-driven and depend
on a linear or non-linear discriminant function. Several representa-
tive examples of linear models include the compound covariate
method proposed by Hedenfalk et al. [12], the shrunken centroid
method by Tibshirani et al. [13], and the optimized linear model
using the partial least square (PLS) technique [11]. Pochet et al.
assessed the effectiveness of non-linearity in cancer classiﬁcation,
and the resulting conclusion is that the non-linear techniques tend
to outperform the linear techniques [14]. The applications of a
number of non-linear methods including k-nearest neighborhood
[6], logistic models [15,16], and factor mixture models [17] toll rights reserved.cancer classiﬁcation further conﬁrmed the conclusion. A number
of neural network techniques have also been developed and
applied to cancer classiﬁcation [10,18–20]. However, due to the
non-typical ‘‘high-dimension and small sample” property of micro-
array data, many neural network classiﬁers exhibit poor general-
ization on unknown data in cancer classiﬁcation problems
[21,22]. In general, the overﬁtting problem tends to occur in the
neural network-based approaches, which were previously
designed for the case where there are a large number of training
samples available in a low-dimensional space. In contrast, the sup-
port vector machine (SVM) technique motivated by statistical
learning theory can achieve a better performance for data of high
dimensionalities and small sample sizes [23–26]. A number of
investigators have developed and applied various kinds of SVMs
to the analysis of gene expression data [9,27–30]. However, as a
data-driven model, SVM cannot interpret the differences between
the various cancer types from a biological viewpoint, and cannot
help to retrieve the related biological information. In recent years,
as an alternative method, model-driven cancer classiﬁcation meth-
ods have received more and more attention [31–33]. For example,
a number of investigators have proposed to model the association
relationships of genes for cancer classiﬁcation [31,34,35]. Antonov
et al. assumed that expression levels of a set of pre-selected genes
are subject to multiple positive and negative correlational relation-
ships with each other [31]. As a result, by adopting a weighted sum
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classiﬁcation model based on biomarker association information.
A main disadvantage of the model is that the same model param-
eters are used for all cancer classes, such that biomarker associa-
tion patterns characteristic to each class cannot be identiﬁed in
an efﬁcient way [36].
From a biological viewpoint, there may exist underlying abnor-
mal biomarker association patterns which are responsible for a
cancer or cancer subtype [37–39]. In this paper, we propose to con-
struct a network model, referred to as Biomarker Association Net-
work (BAN), and apply it to cancer classiﬁcation. The BAN is
different from the concept of a general regulatory network. The
regulatory network aims to understand the cell development pro-
cess of organisms, and is modeled using a time series of biomarker
expression data. For these networks, the following modeling tools
are often used: Boolean networks [40], Bayesian networks and
dynamic Bayesian networks [39,41], or the differential equation
technique [42,43]. We employ neural network theory to model
associations between biomarkers. A large number of methods have
been developed to detect non-trivial changes related to biological
responses in biomarker expression, but most of them have limited
effectiveness due to little or no consideration of biomarker associ-
ation information. Cellular processes often affect sets of biomark-
ers acting in concert. The main focus of our proposed approach is
to detect the associations between the biomarkers, which exhibit
more subtle but consistent changes related to particular cancer
types. To our knowledge, few works have been done on using the
network concept for cancer classiﬁcation because it is not easy to
deﬁne the relationship between a network and a single cancer
sample, and determine the class of a sample by the network.
We model BAN as a fully connected neural network to capture
the biomarker association patterns related to a particular type of
cancer: network nodes represent biomarkers and the connection
weights represent association coefﬁcients between biomarkers.
The input of the BAN denotes the observed expression levels of bio-
markers, while the output denotes the estimated levels by the
association patterns. In view of this objective, we deﬁne an energy
function as a measure of the disagreement between the input and
output of the BAN. The deﬁnition of the energy function enables
the BAN to efﬁciently capture the associations between biomark-
ers, and a classiﬁcation criterion can be easily designed for a net-
work-based classiﬁer. A novel cancer classiﬁcation framework is
then formulated by integrating the BANs of different cancer classes
by a competition mechanism, in which a test sample is classiﬁed
into the class whose BAN has the lowest energy.
We validate our proposed approach on four real-world datasets
including 1 protein expression dataset, nasopharyngeal carcinoma
(NPC) [44], and three gene expression datasets, leukemia [3], colon
[45] and breast [12]. Experimental results show the excellent dis-
criminative power of the BAN-based classiﬁers as well as the effec-
tiveness and efﬁciency of the BANs in capturing the biomarker
associationpatterns responsible for a cancer typeor subtype. Several
conventional classiﬁcation methods including Fisher discriminant
analysis (FDA), k-nearest neighborhood (KNN), Bayesian network
(BN) classiﬁer, support vector machines with linear kernel (linear-
SVM) and radial basis function kernel (rbf-SVM), are comparedwith
our approach, and the comparison results show that the BAN classi-
ﬁers have better performance than the conventional methods.2. Methods
2.1. The framework of the algorithm
The aim of our algorithm is to identify the association patterns
between a small set of biomarkers to facilitate cancer classiﬁcation.Although there are a large number of dynamic variables coming
into play in a biological system, not all take part in a particular bio-
logical process [46–48]. We need to restrict the analysis to a subset
of core biomarkers for a cancer class. In view of this, we determine
key biomarkers from tens of thousands of biomarkers in high-
throughput expression data by considering two factors: single
biomarker correlation degree and combinative performance.
Following the former, we ﬁrst choose a subset of candidate
biomarkers based on two single-variable selection rules, signal-
to-noise-ratio (SNR) [3] and regulation probability (RP) [49], and
then determine a best combination from the subset according to
their cross-validation performances for constructing Biomarker
Association Networks.
For a biomarker, the SNR and RP criteria are, respectively, deter-
mined as follows:
Rsnr ¼ l1  l2r1 þ r2

 ð1Þ
where lc and rc; c ¼ 1;2, represent the mean and standard deriva-
tion of expression levels in a class, and
RRP ¼ 1l jðlu  ldÞj ð2Þ
where l denotes the total number of training samples, lu represents
the number of training samples in which the biomarker is up-regu-
lated, and ld represents the number of training samples in which the
biomarker is down-regulated. We estimate lu and ld using a maxi-
mum likelihood estimation approach [49]. The two criteria are inte-
grated to calculate a combined rank for each biomarker to select the
subset of biomarkers. Speciﬁcally, the combined ranks are calcu-
lated by averaging the two ranks associated with the two criteria.
The SNR and RP criteria focus on different aspects: the former pro-
vides a quantitative measure of the difference between cancer clas-
ses based on their mean expression levels, while the latter assesses
the probability of differential expression between the classes. The
integration of the two criteria can more efﬁciently ﬁlter out irrele-
vant biomarkers which are not essential to cancer classiﬁcation.
To overcome the limitations of the above single-variable selec-
tion, we further employ biomarker combinative performances to
select the best combination from the subset obtained above. The
combinative performance is estimated based on performing strat-
iﬁed k-fold cross-validation on the data sets, and the following
error estimation is used:
Accu ¼ 1 1
G
XG
g¼1
tg
ng
ð3Þ
where tg is the number of correctly classiﬁed samples of the gth
class, ng is the total number of samples in the gth class, and G is
the number of classes. This error criterion can overcome the prob-
lems of small sample and sample imbalance in the biomarker
expression data. In the stratiﬁed cross-validation process, samples
of each class are randomly divided into k equal subsets. One of
the subsets from each class are chosen, and these are combined to
construct a holdout test set, while the remaining data are used for
training. This process is repeated, and the mean error is used to
quantify the classiﬁcation performance. Finally, the best combina-
tion with the lowest mean error is selected, and based on this com-
bination, the proposed algorithm constructs BAN for each cancer
class to perform cancer classiﬁcation. Fig. 1 shows the framework
of the proposed algorithm.
2.2. Linear Biomarker Association Network (LN)
We model the linear Biomarker Association Network (LN) as a
fully connected neural network, as shown in Fig. 2. The underlying
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Fig. 1. Framework of the algorithm.
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with some other biomarkers and can be estimated using a linear
combination. Consider a set of p biomarkers. The input of the LN
represents the observed levels of the p biomarkers, denoted as
x ¼ ½x1; x2; . . . xpT , and the output represents the corresponding
estimated results, denoted as y ¼ ½y1; y2; . . . ; ypT . Let
A ¼ faij 2 R; aii ¼ 0; i; j ¼ 1;2; . . . ; pg denotes the connection matrix
of the network, the operation of the LN can be represented as
follows:
y ¼ Axþ B; B ¼ ½b1; b2; . . . bpT ð4Þ
where bi; i ¼ 1;2; . . . ;p, represents the expression baseline of the ith
biomarker. In addition, A is referred to as the association matrix, of
which each element aij, referred to as association coefﬁcient, repre-11a
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Fig. 2. Biomarker Association Network (BAN).sents the expression effect of biomarker i on biomarker j. The coef-
ﬁcient can be positive or negative: a positive value indicates
expression promotion, and a negative value indicates expression
repression. The constraint aii ¼ 0 is imposed based on the assump-
tion that there is no self-association. The expression baselines can
be viewed as background expression levels that compensate for
the absence of self-association. The structure of the LN is thus
related to that of the auto-associative neural network (refer to [50]).
To analyze a BAN, an energy function, denoted by E, is deﬁned
as a measure of the disagreement between the input and output
of the network, i.e.,
E ¼ 1
2
ðy  xÞTðy  xÞ ð5Þ
which characterizes the dissimilarity between the observed levels
and the estimated levels. Further, substituting Eq. (4) into Eq. (5)
the energy function can be rewritten as
E ¼ 1
2
ðAx xþ BÞTðAx xþ BÞ ð6Þ
From Eq. (6) the energy function only depends on the input of the
BAN and can be used to characterize biomarker association pat-
terns. If a low energy state is maintained for a speciﬁc cancer type,
it is hypothesized that the BAN characterizes an association pattern
responsible for that cancer type and encapsulates it in the parame-
ters A and B. In what follows, an algorithm is developed to obtain a
BAN associated with a particular cancer group.
Let X ¼ ½x1;x2; . . . ;xl denote the set of l known samples of a
cancer class, the association coefﬁcients can be determined
through the minimization of the total energy of the BAN for all l
samples, i.e., by solving the following optimization problem:
Minimize f ¼ 12
Pl
j¼1
ððA IÞxj þ BÞTððA IÞxj þ BÞ
s:t: aii ¼ 0; i ¼ 1;2; . . . ;p
ð7Þ
where I is the identity matrix. Let eA ¼ ðA IÞ, the optimization
problem is reduced to
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Fig. 3. Cancer classiﬁcation system based on BANs. Fed by an input sample x, the
system ﬁrst computes the pattern energy values Ec ; c ¼ 1; . . . ; c by the BANs of each
cancer class, and then outputs a class label vector L.
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P
x2X
ðeAxþ BÞTðeAxþ BÞ
s:t: ~aii ¼ 1; i ¼ 1;2; . . . ;p
ð8Þ
By rewriting eA as ½eA1; eA2; . . . ; eAp, we expand the objective function
as follows:
f ¼ 12 ðeA1X þ b1eÞðeA1X þ b1eÞT þ 12 ðeA2X þ b2eÞ
ðeA2X þ b2eÞT þ    þ 12 ðeApX þ bpeÞðeApX þ bpeÞT
ð9Þ
where e is an l-dimensional row vector consisting of l 1s. As far as
the relationships between biomarkers are mainly concerned, B is
not crucial to the BAN. In fact, by normalizing the expression data
to a mean of zero and a variance of one, B can be reduced to zero.
As a result, for computational convenience, we set B ¼ 0. The objec-
tive function thus reduces to
f ¼ 1
2
ðeA1XÞðeA1XÞT þ 12 ðeA2XÞðeA2XÞT þ    þ
1
2
ðeApXÞðeApXÞT ð10Þ
Further, the function can be rewritten as
f ¼ 12ðU1Z1/1ÞTðU1Z1/1Þþ 12ðU2Z2/2ÞTðU2Z2/2Þþ  
þ12ðUpZp/pÞTðUpZp/pÞ
ð11Þ
where Zi ¼ fxjk; k ¼ 1;2; . . . ; i 1; iþ 1; . . . ; p; j ¼ 1;2; . . . ;ng; Ui ¼
½xi1; xi2; . . . ; xinT , and /i ¼ ½ai1; ai2; . . . ; aiði1Þ; aiðiþ1Þ; . . . ; aipT . By taking
the derivative with respect to /i, we obtain
@f
@/i
¼ ZTi Ui þ ZTi Zi/i ¼ 0; i ¼ 1;2; . . . ;p ð12Þ
and the association coefﬁcients can be obtained as
/i ¼ ðZTi ZiÞ1ZTi Ui; i ¼ 1;2; . . . ;p ð13Þ
If the inverse of ZTi Zi does not exist, the pseudo-inverse can be used
to compute the solution as in [51].
2.3. Non-linear Biomarker Association Network (NLN)
Non-linearity has been shown to provide a better capability to
explore the complex relationships between variables as well as
to efﬁciently reduce noise [52,51]. In view of this, a non-linear
BAN (NLN) is developed to characterize biomarker association pat-
terns. The NLN can be constructed by adding a sigmoid transforma-
tion unit to the LN. In general, other non-linear transformations
can also be used. Let x ¼ ½x1; x2; . . . xpT denotes the input sample,
the corresponding output v ¼ ½v1; v2; . . . ; vpT is determined as
follows:
vi ¼ SigmoidðxiÞ ¼ 1þ e
b xiliri
 20
@
1
A
1
; i ¼ 1;2; . . . ; p ð14Þ
where li and ri represent the mean and standard deviation of the
expression level of biomarker i, respectively, and can be estimated
by training samples. In addition, b 2 ð0;1 is a tunable parameter,
referred to as the sigmoid coefﬁcient. The transformed vector v is
then used as the input to a LN to form a NLN. The energy function
of the NLN can be written as
E ¼ 1
2
ðAv vþ BÞTðAv vþ BÞ ð15Þ
The NLN can be optimized by choosing a proper sigmoid
coefﬁcient.
2.4. Cancer classiﬁcation based on BANs
Considering a C-class cancer classiﬁcation problem, the BAN-
based classiﬁer can be designed by combining the C BANs, asshown in Fig. 3. Given an unknown sample x, the system ﬁrst com-
putes the energy of each BAN Ec; c ¼ 1;2; . . . ;C, and then a winner-
takes-all competition mechanism is applied to determine the BAN
with the minimum energy as the winner. Finally, the system out-
puts a C-dimensional label vector L consisting of ðC  1Þ 0-ele-
ments and one 1-element indicating the predicted class. The idea
behind the cancer classiﬁcation system is that distinct types of can-
cer may be due to different biomarker association patterns.
Fig. 4 provides a geometric interpretation of the BAN-based sys-
tem based on real gene expression data (the leukemia data).
Fig. 4(A) shows the distributions of samples of the two classes in
the expression space based on three optimally selected genes.
From this ﬁgure, it can be seen that the two classes are not well
separated. However, they can be completely separated in the error
space, in which each sample is represented in terms of the sum of
its ﬁtting errors with respective to the association patterns of dif-
ferent classes, and the energy space, in which the samples are rep-
resented in terms of the squared sum of the ﬁtting errors, as shown
in Fig. 4(B) and (C). This result is due to that the class difference is
mainly characterized by hidden association patterns, instead of the
original biomarker expression levels. In particular, the margin
between the two classes is further enlarged in the energy space
when compared to that in the error space, as energy is calculated
as a square function of the ﬁtting errors. Compared with the error
space, the energy space is introduced to highlight the hypothesis
that, rather than performing a simple additive combination of mul-
tiple association patterns, the introduction of non-linear opera-
tions will facilitate the characterization of the interaction
between the different biomarkers. In addition to the optimal genes,
we also illustrate the discriminatory power of the energy function
based on sub-optimal genes, as shown in Fig. 5. Fig. 5(A) indicates
that the three genes do not lead to a good separation of the two
classes in the expression space. However, from Fig. 5(B) in which
the samples are represented in the energy space, it can be seen that
the classes can be distinguished to a certain extent. This ﬁgure pro-
vides further support to the capability of our proposed energy
function to detect differential biomarker association patterns be-
tween various cancer types to facilitate classiﬁcation. The smaller
degree of improvement in the classiﬁcation performance is due
to the sub-optimality of the three selected genes in the current
case, which highlights the necessity of the biomarker selection
process.
To evaluate the classiﬁcation system, we propose a prediction
strength (PS) index. Consider a binary case. According to the above
description, given a sample, the system will compute two energy
values, Ewin and Elose, which correspond to the values of the winning
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Table 1
Classiﬁcation performances of the LN and NLN classiﬁers on the NPC and leukemia
data.
Methods Datasets p ¼ 2 p ¼ 3 p ¼ 4 p ¼ 5 p ¼ 6
LN classiﬁer NPC 0.741 0.778 0.815 0.889 0.815
Leukemia 0.735 0.735 0.794 0.853 0.941
NLN classiﬁer NPC 0.889 0.852 0.889 0.926 0.926
Leukemia 0.853 0.971 1 1 1
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PS index for the predicted sample is computed as follows:
ps ¼ Elose  Ewin
Ewin þ Elose

 ð16Þ
The PS index ranges from 0 to 1 and reﬂects the relative classiﬁca-
tion margin. Ideally, Ewin is equal to zero, and the maximum value of
1 for the prediction strength can be attained.
3. Experimental results
We evaluate our approach on one protein expression dataset,
Nasopharyngeal carcinoma (NPC) [44], and three gene expression
datasets, leukemia [3], colon [45] andbreast [12]. In theNPCdataset,
each patient sample consists of 530 spectra peaks and is labeled as
chemo-responders (RS) or non-responders (NR). The total 54 sam-
ples (44 chemo-responders and 10 non-responders) are allocated
to the training set and testing set, with each having 27 samples
[44]. The leukemia dataset has 72 samples, of which 47 correspond
to acute lymphoblastic leukemia (ALL) and 25 to acute myeloid leu-
kemia (AML), each consisting of the expression levels of 7129 genes.
The leukemia dataset is split into a training set of 38 samples and a
test set of 34 samples as done in [3,31]. The colon dataset consists
of 62 samples, ofwhich 22 are normal and 40 tumor tissue, and each
sample contains the expression levels of 2000 genes [45]. The breast
dataset consists of multiple classes, and is used to test the multi-
class classiﬁcation performance of our approach. The total 22 sam-
ples in the data set are categorized into three classes: 7 with BRCA1
mutation, 8withBRCA2mutation and7 sporadic breast cancers, and
each sample is represented by the expression levels of 3226 genes
[12]. Theadopted trainingand testingmethodologycanbedescribed
as follows: for the datasets with pre-speciﬁed training/test split, we
use the training set to select the best combination of biomarkers to
construct BAN-based cancer classiﬁers, and the test set to evaluate
the performance of the trained classiﬁers. Speciﬁcally, in the bio-
marker combination selection, the SNR-PR integration method is
ﬁrst applied to thewhole training set to choose a subset of biomark-
ers, and then the training set is divided into k folds to evaluate the
cross-validation performance of each combination. For the datasets
without pre-speciﬁed training/test split, we evaluate BAN-based
classiﬁers using a leave-one-out cross-validation approach on the
whole dataset. In each step, one sample is selected for testing, and
the rest are used for training.
3.1. Application to the NPC data
For this data set, we ﬁrst choose a panel of 30 protein biomark-
ers and search for the best biomarker combination from this panel.
The search is performed by initially setting the number of biomark-
ers p to 2, and then gradually increasing this number. The classiﬁ-
cation error of each combination is estimated in the following
manner: we apply stratiﬁed 3-fold cross-validation, and repeat
the process 10 times with different 3-fold splits of samples to
obtain the mean errors. The stratiﬁed cross-validation guarantees
that the original proportion of each class is consistently repre-
sented in both the training and test sets. In the cross-validation
process, samples of each class are divided into three equal subsets.
One subset from each class is chosen, and these are combined to
construct a holdout test set, while the remaining are used for train-
ing. This operation ensures that both training and testing sets have
the same ratio of samples between the different classes as that in
the original data set. Considering the small number of samples in
the expression data set, we set the number of folds to 3. The 10-
time repetition of the cross-validation is used to provide a further
reduction of the variance of the estimated errors. The two types of
BANs, LN and NLN, are, respectively, constructed for the NPC data,B
F
dand for the NLN case, the optimal sigmoid parameter b is chosen
from the set {0.0001,0.001,0.005,0.01,0.05,0.1,0.5}.
Fig. 6(A) shows the evolution curves of the minimum errors
with p ¼ 2—6. From this ﬁgure, it can be seen that the misclassiﬁ-
cation rates of both LN and NLN classiﬁers exhibit similar trends:
they ﬁrst decrease and then reach a minimum. It is also observed
that the NLN classiﬁers attain better training accuracies than the
LN classiﬁers. Table 1 presents the accuracies of these classiﬁers
on the independent test set. It can be seen that the test accuracy
values are consistent with the training ones shown in Fig. 6(A),
irrespective of whether the LN or the NLN classiﬁer is used, which
indicates the good generalization performances of the BAN classi-
ﬁers. From Fig. 6(A) and Table 1, it is also observed that the perfor-
mance of these BAN-based classiﬁers steadily improves with more
biomarkers used, indicating the positive contributions of the addi-
tional relationships captured by the Biomarker Association
Network.
From Table 1, the best test accuracy based on our approach is
92.6%, which is achieved by the ﬁve-biomarker NLN classiﬁer,
and the speciﬁcity and sensitivity are 100% and 80%, respectively.
We then perform further analyses: ﬁrst, we compute the predic-
tion strengths (PS) for the correctly classiﬁed samples by Eq.
(16), and illustrate them in the left-half panel of Fig. 7. From this
ﬁgure, almost all of the PS values are signiﬁcantly higher than
0:4, and the median PS (the horizontal bar) is close to 1 (0.99).
The high PS values further conﬁrm the reliability of the classiﬁer.
Table 2 lists the related biological information of the ﬁve protein
biomarkers involved in the classiﬁer [44], indicating that all the
ﬁve biomarkers are related to the discrimination of NR and RS with
signiﬁcance levels less than 0.05. Fig. 8 compares the expression
distributions of these biomarkers in the RS and NR groups, indicat-
ing that each of them has signiﬁcantly different expression distri-
butions across the two groups.
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Fig. 7. Prediction strengths for the NPC and leukemia datasets. Median PS is
denoted by a horizontal line for each dataset. Almost all of the samples have
signiﬁcantly higher PS values than 0.4.
Table 2
The ﬁve protein biomarkers for the NPC data.
Spectrum name m/z value p-value
M9177_96 9177.96 2.3E-2
M9209_62 9209.62 3.1E-2
M9548_54 9548.54 2.5E-2
M7993_48 7993.48 4.8E-2
M2193_50 2193.50 3.0E-2
660 H.-Q. Wang et al. / Journal of Biomedical Informatics 42 (2009) 654–666Next, the BANs in the classiﬁer are analyzed to discover the dif-
ference of the captured association patterns of the two classes.
Fig. 9 visually compares the two resulting NLNs. In Fig. 9(A) and
(B), red and green lines between nodes represent positive and neg-
ative associations, respectively, and the widths of the lines indicate
the association strength. From the two ﬁgures, it can be seen that
the two NLNs have signiﬁcantly different connection patterns, sug-
gesting that the two groups exhibit different association patterns.
For example, in the RS group, association coefﬁcients between bio-
markers M7993_48 and M2193_50 are positive (0.26 and 0.32),
indicating mutual expression enhancement. However, in the NRRS NR
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Fig. 8. The expression levels of the ﬁve proteins in chemo-respondergroup, the corresponding coefﬁcients become negative (2.89
and 0.34), which indicate mutual repression. Another signiﬁcant
difference is observed when comparing the biomarkers M7993_48
and M9209_62: their coefﬁcients are very small (0.035,0.025) in
the RS group, suggesting that there is little or no association, while
in the NR group, M7993_48 is positively correlated with M9209_62
by a very large coefﬁcient (12.15). Furthermore, the two NLNs have
different dominant biomarkers, as marked in the hexagon nodes in
Fig. 9(A) and (B). Such dominant biomarkers are signiﬁcantly cor-
related with all the other biomarkers, which, as a hub biomarker
of the network, play a crucial role in cancer development [53].
The biomarkers having smaller association coefﬁcients than any
others are marked in the smaller circle nodes in Fig. 9(A) and (B),
which may play only a minor role in the Association Networks.
Similar to the expression proﬁle, we can view an association coef-
ﬁcient as an association channel, and form an association spectrum
for a cancer class by combining all the association channels to gain
a more in-depth understanding of the association patterns associ-
ated with cancer. Fig. 9(C) compares the association levels on each
association channel between the two classes in a bar diagram form,
and Fig. 9(D) shows the association spectra of the two classes
across the whole channel range. The two ﬁgures more clearly indi-
cate the remarkable difference of the association patterns between
the two classes.
We then compare the classiﬁcation performance of the NLN clas-
siﬁer with those of conventional methods including Fisher discrim-
inant analysis (FDA), k-nearest neighborhood (KNN), Bayesian
network classiﬁer (BN) and support vector machines (SVMs) with
both linear kernels (linear-SVM) and radial basis function kernels
(rbf-SVM). Among these conventional methods, the BN classiﬁer,
linear-SVM and rbf-SVM require their parameters to be tuned for
best performance. For the BN classiﬁer, we varied the bin number
in the range {2,3,4,5,6}. For the linear-SVM, we varied the regulari-
zation parameter in the range f212;211; . . . ;21;22g. For the rbf-
SVM, a two-dimensional grid search technique was employed to
optimize the two parameters, regularization factor and kernel
width, with the search ranges of f212;211; . . . ;21;22g and
f24;23; . . . ;29;210g, respectively. These methods were imple-
mented based on the public-domain software WEKA [54]. Table 3−2
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negative associations, respectively, the widths of the lines indicate the strength of association, and the big hexagon nodes indicates the dominant biomarkers of the networks;
(C) comparison of the association levels in each association channel between the two classes; (D) association spectra of the two classes. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 3
Performance comparisons of the NLN classiﬁers with several previous approaches on
the NPC, leukemia and colon data.
Datasets Methods p ¼ 2 p ¼ 3 p ¼ 4 p ¼ 5 p ¼ 6
NPC NLN 0.889 0.852 0.889 0.926 0.926
FDA 0.889 0.815 0.741 0.704 0.815
KNN (k = 3) 0.889 0.852 0.852 0.778 0.889
Linear-SVM 0.815 0.815 0.852 0.852 0.852
rbf-SVM 0.889 0.852 0.852 0.889 0.889
BN 0.852 0.852 0.852 0.852 0.889
Leukemia NLN 0.853 0.971 1 1 1
FDA 0.912 0.853 0.971 0.941 0.941
KNN (k = 3) 0.912 0.882 0.971 0.971 0.971
Linear-SVM 0.882 0.882 0.971 0.971 0.971
rbf-SVM 0.912 0.941 0.971 1 1
BN 0.852 0.941 0.971 1 1
Colon NLN 0.903 0.919 0.936 0.936 0.952
FDA 0.839 0.839 0.839 0.855 0.855
KNN (k = 3) 0.806 0.806 0.855 0.855 0.823
Linear-SVM 0.8395 0.855 0.855 0.855 0.871
rbf-SVM 0.855 0.855 0.887 0.887 0.887
BN 0.806 0.855 0.823 0.806 0.839
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independent test set with different numbers (p) of protein markers
used. From the table, it can be seen that the non-linearmethods tend
to have better classiﬁcation performances.When p ¼ 2 or 3, theNLN
classiﬁer, the KNN and the rbf-SVM attain the same accuracy that is
the highest among the results of all the methods. With p increasing,
the performance of our NLN classiﬁer further improves, while those
of the KNN and rbf-SVM do not. When p ¼ 5, the NLN classiﬁer at-
tains an accuracyof 92.6%,which is signiﬁcantlyhigher than thebest
accuracyof the rbf-SVM(88.9%). In general, ourNLNclassiﬁers attain
higher accuracies than the previous approaches, irrespective of the
number of proteins used. The conventional methods are either lin-
ear, non-linear, or joint probabilistic distribution-based, and are
widely used in bioinformatics and pattern recognition [9,32,25].
Compared with them, our approach has the unique capability of
extracting the association patterns hidden in the expression data,
which accounts for its better performance.
It is well-known that SVM tends to exhibit better performance
for high-dimensional data sets. To explore the potential classiﬁca-
tion performance limit of the NPC dataset, we selected 10, 20, 50,
100 and 200 proteins by the RP and SNR criteria, and re-applied
SVM to the NPC data. Table 4 presents the resulting test accuracies,
indicating that the highest accuracy by SVM is lower than that
(92.6%) of our NLN classiﬁer. The better discrimination power ofour approach is due to the inclusion of the mutual association
information that is not available in SVM. As for the BN classiﬁer,
although it is capable of characterizing the relationships of the dif-
Table 5
The four genes in the four-biomarker NLN classiﬁer for the leukemia data.
Access no. Description
U22376 c-mybgene extracted from human (c-myb)
gene, complete primary cds, and ﬁve complete
alternatively splicedcds
D88422 CYSTATIN A
M23197 CD33 antigen (differentiation antigen)
M12959/X02592 TCRA T cell receptor alpha-chain
Table 4
Test accuracies of SVM using different numbers of proteins for the NPC data.
No. of proteins 10 20 50 100 200
Accuracy 0.852 0.852 0.889 0.889 0.889
662 H.-Q. Wang et al. / Journal of Biomedical Informatics 42 (2009) 654–666ferent variables to a certain extent, the availability of only a small
data sample greatly limits its classiﬁcation performance, as shown
in Table 3.
3.2. Application to the leukemia data
Next, the leukemia data set is used to evaluate our approach.
Fig. 6(b) shows the training errors. Similar to the case of the NPC
dataset, the training errors ﬁrst decrease when more biomarkers
are used, and then reach a minimum. The accuracies of these
BAN classiﬁers on the independent test set are reported in Table
1. From this table, it can be seen that the NLN classiﬁers attain bet-
ter accuracies compared with the LN classiﬁers, similar to the case
of the NPC dataset. More interestingly, three of the ﬁve NLN classi-
ﬁers correctly classify all the independent test samples, and the
least number of genes used is only 4. In the right half panel of
Fig. 6, we show the prediction strengths of the correctly classiﬁed
samples by the four-biomarker NLN classiﬁer. It is clear that all of
the PS values are signiﬁcantly high ð> 0:4Þ and the median PS (the
horizontal bar) is close to 1 (0.999). Table 5 lists the four genes
involved in the NLN classiﬁer. In previous works, the four genes
have been shown to be related to leukemia [3,55,56]. For example,
Gene ‘‘M23197” (CD33 anti-gen) is observed to be over-expressed
in more than 90% of patients with AML, and an anti-CD33 mono-
clonal antibody has been introduced clinically for the treatment
of AML patients [55]. Gene ‘‘D88422” is ranked no. 2 with respect
to the degree of correlation with AML in [56]. Fig. 10(A) and (B)
shows the four-gene NLNs of the AML and ALL classes, respectively,
and Fig. 10(C) and (D) compare the association levels and associa-
tion spectra of the ALL and AML classes, showing the remarkable
differences of the association patterns between the two classes.
Table 3 compares the results of our NLN classiﬁer with those of
previous approaches including FDA, KNN, BN classiﬁer and SVM
with linear and rbf kernels, showing that our NLN classiﬁers attain
the highest classiﬁcation accuracies, irrespective of the number of
genes used. Table 6 presents the previous results by other
researchers, which further conﬁrms the high accuracy of our pro-
posed approach. In addition to the validation on the independent
test set, we also performed the leave-one-out cross-validation
(LOOCV) on all the samples for the leukemia dataset, and the
obtained results are compared with those reported by other
researchers in Table 7. From Table 7, it can be seen that our NLN
classiﬁer can correctly classify all the 72 samples, which is signiﬁ-
cantly better than all but one of the results.
3.3. Application to the colon data
Different from the above two datasets, the colon dataset does
not have a standard training/test split, and most researchersadopted LOOCV to evaluate their algorithms when using this data-
set [11,14]. For convenient comparison, in this study our BAN-
based approach is also evaluated using LOOCV. Table 3 reports
the classiﬁcation results of our NLN classiﬁer and compares them
with those of the previous approaches including FDA, KNN, BN
and SVMs. From this table, it can be seen that the NLN classiﬁer
signiﬁcantly outperforms the other classiﬁers in classiﬁcation
accuracy, irrespective of the number of genes used. In particular,
our six-gene NLN classiﬁer can attain the highest accuracy of
95.2%. Table 8 further compares our results with the previously
reported results, showing that our result is signiﬁcantly better than
all but one of the results. Table 9 reports the previous 3- or 10-fold
cross-validation results for the colon data, showing that most of
the classiﬁcation accuracy values are lower than 0.90. Based on
the six-gene model, we computed the mean association levels
and the mean association spectra for each class, and show them
in Fig. 11(A). This ﬁgure indicates the remarkable difference of
the association patterns of the two classes.
3.4. Application to the breast data
The breast data set is about a three-class cancer classiﬁcation
problem, and is used here to evaluate the multi-class classiﬁcation
performance of our approach. Considering the small sample size
(22) of the data set, we adopt LOOCV evaluation in this experiment.
Fig. 12 shows the classiﬁcation results of our NLN classiﬁer with
different p and compares them with those of the KNN classiﬁers
with different numbers of neighbors k (from 2 to 5) and the BN
classiﬁer. From this ﬁgure, it can be seen that the NLN classiﬁers
using four or six gene biomarkers attained an accuracy of 100%,
i.e., correctly classifying all the samples, which is better than the
results of the other approaches. Fig. 12 also suggests that the accu-
racy of the NLN classiﬁer steadily increases when more biomarkers
are used, similar to the cases of the above three data sets. The suc-
cessful classiﬁcation of the breast dataset conﬁrms the multi-class
cancer classiﬁcation capability of our BAN-based approach, and
lends more support to the effectiveness of the association patterns
captured by the BAN models. Based on the six-gene model,
Fig. 11(B) shows the mean association levels and the mean associ-
ation spectra of the three breast cancer types (BRCA1 mutation,
BRCA2 mutation and sporadic tissue), indicating the remarkable
difference of the association patterns between the three breast
cancer types.
For the breast data, two binary classiﬁcation problems from the
three classes (BRCA1, BRCA2 and sporadic) have been addressed by
other researchers based on either the 3-fold or LOOCV approach
[57,14,58]. Table 10 lists the reported results. Compared with these
results, our NLN approach not only simultaneously classiﬁes the
three subtypes of breast cancer, instead of only two subtypes,
but also attains the maximum accuracy of 100%.
3.5. Inﬂuence of the non-linear transformation
From the above four applications, it can be seen that the NLN
classiﬁers perform better than the LN ones. We hypothesize that
the non-linear transformation in the NLN classiﬁers plays a crucial
role in the improvement of performance. The sigmoid coefﬁcient b
is an important parameter of the sigmoid function, which controls
the non-linear transformation and can improve the separability of
the original data by reducing noise [52,51]. To investigate the inﬂu-
ence of this coefﬁcient and possibly obtain some guidelines for its
choice, we investigate the classiﬁcation performance of the NLN
classiﬁer under different values of b based on the above four real
datasets. Fig. 13 shows the change of the classiﬁcation accuracies
with respective to b. From Fig. 13, it is seen that a suitable range
of b is [0.001,0.1].
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Fig. 10. The association patterns for the two classes of the leukemia data. (A) BAN of the ALL class and (B) BAN of the AML class, where red and green lines represent positive
and negative associations, respectively, the widths of the lines indicate the strength of associations, and the big hexagon nodes indicate the dominant biomarkers of the
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Table 6
Previous results on the test set for the leukemia data.
Methods No. of genes Accuracies
RPLS [15] 50 0.971
RPCR [15] 50 0.971
Factor mixture models [17] 242 0.94
PCA/SFFS/SVM [63] – 0.94
ICA/SFFS/SVM [63] – 1
S2N correlation/SVM [64] Not more than 64 0.971
FC correlation/SVM [64] Not more than 64 0.912
‘‘Expected” SVM-RFE/SVM [64] Not more than 64 0.962
Two-stage SVM-RFE/SVM [64] Not more than 64 1
Table 7
Comparison of the LOOCV results of our NLN classiﬁer with several previously
reported ones on the leukemia data.
Methods No. of genes Accuracies
Our NLN classiﬁer 4 1
Logistic regression method [16] 20 0.972
RPLS [15] 50 1
RPCR [15] 50 0.972
Neuro-fuzzy ensemble machine [65] 20 0.958
FREM/SVM [66] 25 0.986
Bayesian variable selection approach [56] 5 0.972
Table 8
Comparison of the LOOCV results of the NLN classiﬁer with previously reported
results on the colon data.
Methods No. of genes Accuracies
Our NLN classiﬁer 6 0.952
QDA/t-score/PLC [11] 50 0.919
RPLS [15] 100 0.887
RPCR [15] 1000 0.887
MFMW [67] 6 0.952
SFSW [67] 10 0.903
Entropy-based method [68] 31 0.903
Table 9
Previous 3-/10-fold cross-validation results for colon data.
Methods k-fold Accuracies
ACA/LVM [69] 10-fold 0.933
REDISC/PLS/SVM [70] 10-fold 0.866
RELIC/PCA/SVM [70] 10-fold 0.863
Rule groups [71] 10-fold 0.914
GA-MTL [72] 3-fold 0.857
MPE/SVM [57] 3-fold 0.879
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In the proposed BAN model, the association patterns are encap-
sulated in the connection weights, and the expression level of a
biomarker is estimated based on these patterns. The estimated val-
ues should be compared with the observed one to determine2 3 4 5 6
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Fig. 12. Performance comparison of our NLN classiﬁer with several previous
methods on the breast data.whether the patterns can efﬁciently explain a given biomarker
expression proﬁle. As a result, we deﬁne an energy function as a
measure of the discrepancy between the estimated and observed
values. More and more studies indicate that abnormal epigenetic
change plays a critical role in cancer development, and biomarker
expression information serves as an important indicator of
neoplastic initiation and progression [59]. The biomarker associa-
tion patterns detected using our approach may more consistently
account for different cancer types, and are more stable than
expression patterns across different samples. In particular, the
non-linearity of the model can further facilitate the modeling of
the complex epigenetic change, and the effectiveness has been
conﬁrmed through our experiments.
Since our model implies that different types or subtypes of can-
cer correspond to different BANs, each network has a high speciﬁc-
ity for a particular cancer type. Compared with conventionalTable 10
Previous LOOCV and 3-fold cross-validation results of binary classiﬁcation for the
breast data.
Methods k-fold Binary problems Accuracies
MPE/SVM [57] 3-fold BRCA1 vs rest 1
BRCA2 vs rest 1
LS-SVM with rbf kernel [14] 3-fold BRCA1 vs rest 0.75
BRCA2 vs rest 0.88
Linear probit Bayesian
classiﬁer [58]
LOOCV BRCA1 vs rest 0.909
Non-linear probit Bayesian
classiﬁer [58]
LOOCV BRCA1 vs rest 1
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Fig. 13. Inﬂuence of the sigmoid coefﬁcient on the classiﬁcation performance of the
NLN classiﬁer.
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ian network, the BAN model can quantify an association between
biomarkers in the form of a real coefﬁcient. The BAN model high-
lights the difference of biomarker association patterns between
different cancer types or subtypes, and provides an association
spectrum representation for a better understanding of cancer from
a biomarker association angle. Different manifestations of the
same type of cancer, while corresponding to highly variable ranges
of expression values for the different biomarkers, can have similar
association spectra. Feedback serves as an important mechanism to
maintain stability, and plays a prominent role in biomarker activ-
ity, in particular for keeping the dynamic balance of the cellular
system and endowing cells with the self-repairing ability against
unexpected changes in the outer environment [60]. The bi-direc-
tional association coefﬁcients reﬂect this kind of feedback. In addi-
tion, the BAN model can be incrementally expanded through a
step-by-step judicious inclusion of related biomarkers, thus facili-
tating the construction of a large-scale network.
5. Conclusion and discussion
We have proposed a new cancer classiﬁcation approach based
on the concept of a Biomarker Association Network (BAN). In this
approach, a neural network structure is proposed to model the bio-
marker association patterns responsible for cancer. In particular,
an energy function is designed as a measure of the disagreement
between the observed levels of biomarker expression and the esti-
mated levels so that the association coefﬁcients can be determined
by minimizing the energy function. We develop two types of BANs,
LN and NLN, for cancer classiﬁcation. The proposed approaches are
evaluated on four publicly available data sets including one protein
expression data, the NPC dataset, and three gene expression data
sets, the leukemia, the colon and the breast cancer data, and the
experimental results show that the proposed BAN-based classiﬁca-
tion approaches, in particular, the NLN classiﬁer, achieve excellent
classiﬁcation performances on the four datasets. Extensive com-
parisons with ﬁve previous classiﬁcation methods, FDA, KNNs,
BN, SVMs with linear and non-linear kernels, are performed, which
further conﬁrm the superior performance of the NLN classiﬁer. As
well as providing high accuracy of cancer classiﬁcation, the pro-
posed approaches can also allow us to gain an understanding of
the complex relationships between the various biomarkers from
a biological viewpoint. Based on the real-world datasets, remark-
ably large differences of the association coefﬁcients can be identi-ﬁed between different cancer types, reﬂecting the signiﬁcantly
different underlying biomarker association patterns.
In this study, the proposed BANmodel is applied to characterize
biomarker expression proﬁle data associated with cancer, which
may not include a temporal element, for the purpose of classiﬁca-
tion. In particular, the connections of the network represent spe-
ciﬁc association relationships between biomarkers which are
related to cancer, and the associated weights of these connections
are estimated based on empirical data. This Association Network
differs from a general regulatory network in that, for the latter,
the expression of a biomarker is controlled by its regulatory ele-
ments, and the regulated result will be observed only after a cer-
tain delay. In other words, while temporal data are necessary to
determine the regulatory relationships between biomarkers in
the case of a regulatory network [41,61,62], the inclusion of these
type of data is not mandatory for the approximate characterization
of the relationships between biomarkers in the case of an Associa-
tion Network.
A limitation of the proposed approach is the expensive compu-
tation cost for the case when too many biomarkers are considered.
Fortunately, we only focus on a few association patterns associated
with cancer classiﬁcation, and there are a number of approaches
for seeking a small set of involved biomarkers. More importantly,
with the increasing amount of information available in data repos-
itories such as Gene Ontology, KEGG and GenMAPP, the search
space can be efﬁciently reduced based on these prior knowledge.
In addition, distributed computing technique can serve as an effec-
tive solution to improve the computational efﬁciency. Our future
works will focus on exploring more efﬁcient non-linear forms of
BANs and developing large-scale BAN structures for the under-
standing of biomarker association patterns of cancer.Acknowledgment
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